FILINGS
| AZN 0000901832 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2023-02-24 | SC TO-T/A | SC TO-T/A | View Document |
| 2023-02-23 | 6-K | ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 | View Document |
| 2023-02-23 | SC TO-T/A | SC TO-T | View Document |
| 2023-02-22 | 6-K | FILING OF FORM 20-F WITH SEC | View Document |
| 2023-02-21 | 6-K | FORM 6-K | View Document |
| 2023-02-21 | IRANNOTICE | IRANNOTICE | View Document |
| 2023-02-21 | 20-F | FORM 20-F | View Document |
| 2023-02-21 | 6-K | ANNUAL FINANCIAL REPORT | View Document |
| 2023-02-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2023-02-10 | SC 13G/A | SC 13G/A | View Document |
| 2023-02-10 | SC 13G/A | SC 13G/A | View Document |
| 2023-02-09 | 6-K | FINAL RESULTS | View Document |
| 2023-02-03 | SC TO-T/A | SC TO-T/A | View Document |
| 2023-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2023-01-26 | 6-K | UPDATE ON EVUSHELD US EUA | View Document |
| 2023-01-24 | SC 13G/A | View Document | |
| 2023-01-23 | SC TO-T | SC TO-T | View Document |
| 2023-01-17 | 6-K | ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED | View Document |
| 2023-01-11 | 6-K | AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA | View Document |
| 2023-01-09 | SC TO-C | SC TO-C | View Document |
| 2023-01-09 | 6-K | ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET | View Document |
| 2023-01-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-12-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-12-28 | 6-K | CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL | View Document |
| 2022-12-28 | 6-K | IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS | View Document |
| 2022-12-21 | 6-K | IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER | View Document |
| 2022-12-21 | 6-K | LYNPARZA APPROVED IN EU FOR PROSTATE CANCER | View Document |
| 2022-12-19 | 6-K | ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME | View Document |
| 2022-12-19 | 6-K | ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD | View Document |
| 2022-12-19 | 6-K | IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT | View Document |
| 2022-12-19 | 6-K | UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL | View Document |
| 2022-12-19 | 6-K | FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF | View Document |
| 2022-12-15 | 6-K | UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA | View Document |
| 2022-12-08 | 6-K | CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER | View Document |
| 2022-12-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-12-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2022-11-30 | 6-K | ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE | View Document |
| 2022-11-29 | 6-K | ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS | View Document |
| 2022-11-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-11-14 | 6-K | ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC | View Document |
| 2022-11-14 | 6-K | IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC | View Document |
| 2022-11-14 | 6-K | LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC | View Document |
| 2022-11-14 | 6-K | IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER | View Document |
| 2022-11-10 | 6-K | YTD AND Q3 2022 RESULTS | View Document |
| 2022-11-09 | 6-K | FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA | View Document |
| 2022-11-04 | 6-K | BEYFORTUS (NIRSEVIMAB) APPROVED IN EU | View Document |
| 2022-11-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-10-26 | 6-K | CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS | View Document |
| 2022-10-25 | 6-K | UPDATE ON MESSINA PHASE III TRIAL | View Document |
| 2022-10-24 | 6-K | IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER | View Document |
| 2022-10-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-09-30 | 6-K | BOARD COMMITTEE CHANGES | View Document |
| 2022-09-27 | 6-K | KOSELUGO APPROVED IN JAPAN FOR NF1 | View Document |
| 2022-09-27 | 6-K | TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA | View Document |
| 2022-09-23 | 6-K | ULTOMIRIS APPROVED IN EU FOR GMG | View Document |
| 2022-09-22 | 6-K | LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER | View Document |
| 2022-09-21 | 6-K | TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA | View Document |
| 2022-09-20 | 6-K | EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT | View Document |
| 2022-09-16 | 6-K | DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 2022-09-16 | 6-K | NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP | View Document |
| 2022-09-16 | 6-K | EVUSHELD POSITIVE CHMP OPINION IN EU | View Document |
| 2022-09-06 | 6-K | FORXIGA APPROVED IN CHINA FOR CKD | View Document |
| 2022-09-06 | 6-K | IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER | View Document |
| 2022-09-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-08-30 | 6-K | EVUSHELD APPROVED FOR COVID-19 IN JAPAN | View Document |
| 2022-08-30 | 6-K | FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF | View Document |
| 2022-08-30 | 6-K | FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE | View Document |
| 2022-08-25 | 6-K | ULTOMIRIS APPROVED IN JAPAN FOR GMG | View Document |
| 2022-08-25 | 6-K | TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER | View Document |
| 2022-08-25 | 6-K | LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER | View Document |
| 2022-08-16 | 6-K | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL | View Document |
| 2022-08-15 | 6-K | ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 | View Document |
| 2022-08-12 | 6-K | ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC | View Document |
| 2022-08-11 | 6-K | ACQUISITION OF TENEOTWO COMPLETED | View Document |
| 2022-08-08 | 6-K | ENHERTU APPROVED IN THE US FOR HER2-LOW MBC | View Document |
| 2022-08-04 | 6-K | LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER | View Document |
| 2022-08-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-08-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2022-07-29 | 6-K | FORM 6-K | View Document |
| 2022-07-29 | 6-K | CHAIR SUCCESSION | View Document |
| 2022-07-25 | 6-K | TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA | View Document |
| 2022-07-25 | 6-K | ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG | View Document |
| 2022-07-25 | 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC | View Document |
| 2022-07-19 | 6-K | ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC | View Document |
| 2022-07-08 | SC 13G | View Document | |
| 2022-07-05 | 6-K | ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER | View Document |
| 2022-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-06-30 | 6-K | IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER | View Document |
| 2022-06-29 | 11-K | ANNUAL REPORT | View Document |
| 2022-06-27 | 6-K | ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL | View Document |
| 2022-06-27 | 6-K | LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER | View Document |
| 2022-06-21 | 6-K | EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS | View Document |
| 2022-06-10 | 25-NSE | View Document | |
| 2022-06-09 | 25-NSE | View Document | |
| 2022-06-06 | 6-K | ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER | View Document |
| 2022-06-01 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2022-06-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2022-05-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
